GlassScriptPhysician profile
Tausif Sayied
NPI 1417973793
$6,728.08
in general payments reported to CMS, 2019-2025
41 companies · $1,721 in 2025
The $1,721 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $438 · 2020: $620 · 2021: $771 · 2022: $832 · 2023: $959 · 2024: $1,387 · 2025: $1,721.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,840 · Education: $227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,840.13 |
| Education | $226.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $810.01 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Pfizer INC. | $702.79 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $600.72 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $536.47 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Harmony Biosciences LLC | $534.95 | 2020-2025 | Wakix |
| Mylan Specialty L.P. | $368.77 | 2019-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $344.22 | 2019-2025 | Dupixent, Libtayo |
| Insmed, INC. | $317.29 | 2020-2025 | Arikayce, Brinsupri |
| Jazz Pharmaceuticals INC. | $276.87 | 2020-2025 | |
| Actelion Pharmaceuticals US, INC. | $236.75 | 2021-2025 | Uptravi, Opsumit |
| Axsome Therapeutics, INC. | $219.01 | 2023-2025 | Sunosi |
| Genzyme Corporation | $163.51 | 2020-2025 | |
| Grifols USA, LLC | $153.31 | 2020-2025 | Prolastin-C Liquid |
| Sunovion Pharmaceuticals INC. | $147.86 | 2019-2021 | |
| Viatris Specialty LLC | $134.81 | 2025 | Yupelri |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $133.22 | 2023-2025 | Recarbrio, Zerbaxa, Dificid |
| Csl Behring | $116.33 | 2019-2024 | Kcentra |
| United Therapeutics Corporation | $111.73 | 2021-2025 | Tyvaso, Tyvaso |
| Genentech USA, INC. | $78.98 | 2019-2023 | Xolair |
| Baxter Healthcare | $69.31 | 2022-2024 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Amgen INC. | $65.42 | 2022-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $65.12 | 2021-2023 | Glassia |
| Bayer Healthcare Pharmaceuticals INC. | $64.16 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $54.22 | 2020-2021 | |
| Pharming Healthcare, INC. | $51.88 | 2023-2024 | Ruconest |
| Janssen Pharmaceuticals, INC | $43.83 | 2020-2022 | |
| Ani Pharmaceuticals, INC. | $36.56 | 2023 | Purified Cortrophin Gel |
| Avadel Cns Pharmaceuticals, LLC | $34.70 | 2024 | Lumryz |
| Fisher & Paykel Healthcare INC | $28.57 | 2019-2025 | Fisher & Paykel Healthcare |
| Resmed Corp | $28.05 | 2022-2023 | |
| Allergan, INC. | $27.42 | 2020 | |
| Philips North America LLC | $23.53 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $22.76 | 2025 | |
| Verona Pharma, INC. | $19.42 | 2025 | Ohtuvayre |
| Lilly USA, LLC | $16.66 | 2025 | Zepbound |
| Advanced Respiratory, INC | $16.38 | 2019 | |
| Mayne Pharma Commercial LLC | $16.05 | 2021 | |
| Chiesi USA, INC. | $15.81 | 2019 | |
| Ambu INC. | $14.64 | 2023 | |
| Electromed, INC. | $13.88 | 2025 | Smartvest |
| E.R. Squibb & Sons, L.L.C. | $12.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tausif Sayied listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.